| Name | Title | Contact Details |
|---|
Calimmune, Inc., a clinical-stage human immunodeficiency virus (HIV) gene medicines company, develops cell-based therapies for HIV. The company offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. It also focuses on developing products to address the needs of various types of individuals at different states of HIV infection and with different levels of treatment experience..
The Difference Card helps organizations build the most cost effective health plan. Since 2001, The Difference Card has provided its clients with an average net savings of over 18%. The product utilizes proprietary medical reimbursement systems, risk transfer solutions and wellness strategies. In doing so, The Difference Card has delivered millions of dollars in savings to its clients while at the same time providing the highest level of employee benefits. With 13 offices across the United States, The Difference Card provides a national presence combined with local expertise and service. Through strategic broker partnerships, The Difference Card delivers custom plan design solutions that exceeds the needs of both employers and employees across the country.
Truman Medical Centers (TMC) has all the things you expect from a great health system. With two, acute care academic hospital locations, a behavioral health program, a long term care facility and multiple primary care practices, TMC provides care from birth through your senior years. TMC Hospital Hill, in downtown Kansas City, is the busiest Level One Trauma Center in the city. From the healing environment of 400 works of museum quality art to our seasonal produce market, you can count on something special at TMC. We provide the full range of services with specialties in chronic disease management, high risk pregnancy and sleep disorders along with the brand new state of the art Richard and Annette Bloch Cancer Center. In eastern Jackson County, TMC Lakewood sits on 300 acres of beautiful wooded grounds, with a nature walking trail and scenic views, our facility is the epitome of comfort and care. We have all the services you would expect a community hospital from emergency medicine to a nationally-certified orthopaedic joint replacement program as well as a labor and delivery unit that provides comfort and care for the whole family. We have several community-based family medical care centers and a radiology center that provides the latest in technology and specialized breast cancer care that includes a board certified plastic and reconstructive surgeon close to home.
Curve Health is senior care without walls. Founded in April of 2020 on a platform that`s reduced patient transfers from Skilled Nursing Facilities (SNFs) to Emergency Departments by 50%+, Curve advances connected senior care by bridging the silos that hinder healthcare delivery today; enabling physicians to remotely care for patients in SNFs, at home, in ambulances or wherever they may be. Curve combines telemedicine, a health information exchange, predictive analytics and smart billing into a single platform, resulting in higher quality care + significant return on investment, while ensuring the most seamless patient experience.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.